2-{1-[4-amino-3-(3-fluoro-4-isopropoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl}-3-phenyl-3H-quinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{1-[4-amino-3-(3-fluoro-4-isopropoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl}-3-phenyl-3H-quinazolin-4-one
• 英文别名: 2-[1-[4-Amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl]-3-phenylquinazolin-4-one；2-[1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl]-3-phenylquinazolin-4-one
• 化学式: C₃₁H₂₈FN₇O₂
• 分子量: 549.607
• InChiKey: DOHHYJPEXPPBHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2’-氨基苯甲酰苯胺 在 4-二甲氨基吡啶 、 potassium carbonate 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三氯氧磷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 2-{1-[4-amino-3-(3-fluoro-4-isopropoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl}-3-phenyl-3H-quinazolin-4-one
  参考文献：
  名称：

  [EN] PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS
  [FR] INHIBITEURS DE PROTÉINE KINASE PI3K, EN PARTICULIER INHIBITEURS DELTA ET/OU GAMMA

  摘要：

  本公开提供了一种作为PI3K蛋白激酶调节剂有用的新化合物（I），特别是作为PI3K δ（8）和/或γ（γ）蛋白激酶调节剂。本公开还提供了制备PI3K蛋白激酶调节剂的方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善PI3K激酶介导的疾病或疾病的方法。

  公开号：

  WO2015001491A1

文献信息

• PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS
  申请人：RHIZEN PHARMACEUTICALS SA

  公开号：US20160207929A1

  公开（公告）日：2016-07-21

  The present disclosure provides novel compounds useful as PI3K protein kinase modulators, in particular as PI3K delta (δ) and/or gamma (γ) protein kinase modulators. The present disclosure also provides methods for preparing PI3K protein kinase modulators, pharmaceutical compositions containing them, and methods of treatment, prevention and/or amelioration of PI3K kinase mediated diseases or disorders with them.

  本公开提供了一种新型化合物，可用作PI3K蛋白激酶调节剂，特别是PI3K delta(δ)和/或gamma(γ)蛋白激酶调节剂。本公开还提供了制备PI3K蛋白激酶调节剂的方法，包含它们的制药组合物以及使用它们治疗、预防和/或缓解PI3K激酶介导的疾病或疾病的方法。
• Compounds for reducing c-Myc in c-Myc overexpressing cancers background
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10882863B2

  公开（公告）日：2021-01-05

  The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to administration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.

  本发明涉及可降低 c-Myc 表达并可用于癌症治疗的新化合物，特别是血液肿瘤，如侵袭性 B 细胞和 T 细胞淋巴瘤。新化合物可与辅助性 c-Myc 抑制剂如 PI3K 抑制剂、CK-1 抑制剂、Akt-抑制剂、蛋白酶体抑制剂和/或 mTor 抑制剂结合使用。c-Myc还原剂可作为先导疗法，在使用辅助癌症治疗剂之前减少或开始减少c-Myc。使用c-Myc还原剂治疗可调节c-Myc过表达癌症的疾病状态，使其恶性程度降低，更容易接受辅助癌症疗法。
• PI3K protein kinase inhibitors
  申请人：Rhizen Pharmaceuticals SA

  公开号：US11352359B2

  公开（公告）日：2022-06-07

  The present disclosure provides novel compounds useful as PI3K protein kinase modulators, in particular as PI3K delta (δ) and/or gamma (γ) protein kinase modulators. The present disclosure also provides methods for preparing PI3K protein kinase modulators, pharmaceutical compositions containing them, and methods of treatment, prevention and/or amelioration of PI3K kinase mediated diseases or disorders with them.

  本公开提供了可用作 PI3K 蛋白激酶调节剂的新型化合物，特别是 PI3K δ（δ）和/或 γ（γ）蛋白激酶调节剂。本公开还提供了制备 PI3K 蛋白激酶调节剂的方法、含有它们的药物组合物，以及用它们治疗、预防和/或改善 PI3K 激酶介导的疾病或紊乱的方法。
• Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20190194212A1

  公开（公告）日：2019-06-27

  The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.
• [EN] COMPOUNDS FOR REDUCING C-MYC IN C-MYC OVEREXPRESSING CANCERS<br/>[FR] COMPOSÉS POUR FAIRE DIMINUER C-MYC DANS LES CANCERS SUREXPRIMANT C-MYC
  申请人：UNIV COLUMBIA

  公开号：WO2018013213A1

  公开（公告）日：2018-01-18

  The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.